Regulation of the alternative splicing of sarcoplasmic reticulum Ca 2+-ATPase1 (SERCA1) by phorbol 12-myristate 13-acetate (PMA) via a PKC pathway

Biochemical and Biophysical Research Communications

Volumn 423, Issue 2, 2012, Pages 212-217

  Zhao, Yimeng ^a   Koebis, Michinori ^a   Suo, Satoshi ^a   Ohno, Shigeo ^b   Ishiura, Shoichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Alternative splicing; CUG binding protein 1 (CUGBP1); Myotonic dystrophy; Phorbol 12 myristate 13 acetate (PMA); PKC; Sarcoplasmic endoplasmic reticulum Ca 2+ ATPase 1 (SERCA1)

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C BETA; PROTEIN KINASE C THETA; PROTEIN SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; RNA INTERFERENCE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 1 GENE; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; EXONS; HEK293 CELLS; HUMANS; INDOLES; MYOTONIC DYSTROPHY; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 84862867184     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.033     Document Type: Article

References (35)

1. Ranum L.P., Day J.W. Myotonic dystrophy: RNA pathogenesis comes into focus. Am. J. Hum. Genet. 2004, 74:793-804.
2. Mankodi A., Takahashi M.P., Jiang H., et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 2002, 10:35-44.
3. Ho T.H., Charlet B.N., Poulos M.G., et al. Muscleblind proteins regulate alternative splicing. EMBO J. 2004, 23:3103-3112.
4. Hino S., Kondo S., Sekiya H., et al. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Hum. Mol. Genet. 2007, 16:2834-2843.
5. Kanadia R.N., Johnstone K.A., Mankodi A., et al. A muscleblind knockout model for myotonic dystrophy. Science 2003, 302:1978-1980.
6. Hao M., Akrami K., Wei K., et al. Muscleblind-like 2 (Mbnl2) -deficient mice as a model for myotonic dystrophy. Dev. Dyn. 2008, 237:403-410.
7. Mykowska A., Sobczak K., Wojciechowska M., et al. CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res. 2011, 39:8938-8951.
8. Wheeler T.M., Sobczak K., Lueck J.D., et al. Thornton, Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325:336-339.
9. Mulders S.A., van den Broek W.J., Wheeler T.M., et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Nat. Acad. Sci. U.S.A 2009, 106:13915-13920.
10. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270:1628-1644.
11. Nishida A., Kataoka N., Takeshima Y., et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat. Commun. 2011, 2:308. 10.1038/ncomms1306.
12. O'Leary D.A., Vargas L., Sharif O., et al. HTS-compatible patient-derived cell-based assay to identify small molecule modulators of aberrant splicing in myotonic dystrophy type 1. Curr. Chem. Genomics 2010, 4:9-18.
13. Logigian E.L., Martens W.B., Moxley R.T., et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010, 74:1441-1448.
14. Toyoshima C., Nakasako M., Nomura H., et al. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature 2000, 405:647-655.
15. Zádor E., Mendler L., Ver Heyen M., et al. Changes in mRNA levels of the sarcoplasmic/endoplasmic-reticulum Ca(2+)-ATPase isoforms in the rat soleus muscle regenerating from notexin-induced necrosis. Biochem. J. 1996, 320:107-113.
16. Zádor E., Dux L., Wuytack F. Prolonged passive stretch of rat soleus muscle provokes an increase in the mRNA levels of the muscle regulatory factors distributed along the entire length of the fibers. J. Muscle Res. Cell Motil. 1999, 20:395-402.
17. Ho T.H., Bundman D., Armstrong D.L., et al. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum. Mol. Genet. 2005, 14:1539-1547.
18. Tang Z.Z., Yarotskyy V., Wei L., et al. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel. Hum. Mol. Genet. 2012, 21:1312-1324.
19. Kuyumcu-Martinez N.M., Wang G.S., Cooper T.A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Molecular Cell 2007, 28:68-78.
20. Wang G.S., Kuyumcu-Martinez M.N., Sarma S., et al. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J. Clin. Invest. 2009, 119:3797-3806.
21. Irie N., Sakai N., Ueyama T., et al. Subtype- and species-specific knockdown of PKC using short interfering RNA. Biochem. Biophys. Res. Commun. 2002, 298:738-743.
22. Sakai H., Yamamoto M., Kozutsumi Y., et al. Identification of PKC isoforms expressed in human bronchial smooth muscle cell. J. Smooth Muscle Res. 2009, 45:55-62.
23. Nagata K.I., Okano Y., Nozawa Y. Protein kinase C isozymes in human megakaryoblastic leukemia cell line, MEG-01: possible involvement of the isozymes in the differentiation process of MEG-01 cells. Br. J. Haematol. 1996, 93:762-771.
24. Hayashi A., Seki N., Hattori A., et al. PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu. Biochim. Biophys. Acta. 1999, 1450:99-106.
25. Orr J.W., Newton A.C. Intrapeptide regulation of protein kinase C. J. Biol. Chem. 1994, 269:8383-8387.
26. Nowak G. Protein kinase C mediates repair of mitochondrial and transport functions after toxicant-induced injury in renal cells. J. Pharmacol Exp. Ther. 2003, 306:157-165.
27. Meyer M.C., Kell P.J., Creer M.H., et al. Calcium-independent phospholipase A2 is regulated by a novel protein kinase C in human coronary artery endothelial cells. Am. J. Physiol. Cell Physiol. 2005, 288:C475-C482.
28. Disatnik M.H., Boutet S.C., Lee C.H., et al. Sequential activation of individual PKC isozymes in integrin-mediated muscle cell spreading: a role for MARCKS in an integrin signaling pathway. J. Cell Sci. 2002, 115:2151-2163.
29. Di A., Gao X.P., Qian F., et al. The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nat. Immunol. 2011, 13:29-34.
30. Revil T., Toutant J., Shkreta L., et al. Protein kinase C-dependent control of Bcl-x alternative splicing. Mol. Cell. Biol. 2007, 27:8431-8441.
31. Lynch K.W., Weiss A. A model system for activation-induced alternative splicing of CD45 pre-mRNA in T cells implicates protein kinase C and Ras. Mol. Cell Biol. 2000, 20:70-80.
32. Rosenberger U., Lehmann I., Weise C., et al. Identification of PSF as a protein kinase Calpha-binding protein in the cell nucleus. J. Cell Biochem. 2002, 86:394-402.
33. Osada S., Mizuno K., Saido T.C., et al. A new member of the protein kinase C family, nPKCθ, predominantly expressed in skeletal muscle. Mol. Cell Biol. 1992, 12:3930-3938.
34. Baier G., Telford D., Giampa L., et al. Molecular cloning and characterization of PKCθ, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells. J. Biol. Chem. 1993, 268:4997-5004.
35. Madaro L., Pelle A., Nicoletti C., et al. PKC theta ablation improves healing in a mouse model of muscular dystrophy. PLoS One 2012, 7:e31515. 10.1371/journal.pone.0031515.